Publications en collaboration avec des chercheurs de University of Cagliari (9)

2020

  1. ADHD management during the COVID-19 pandemic: guidance from the European ADHD Guidelines Group

    The Lancet Child and Adolescent Health

2018

  1. Practitioner review: Current best practice in the use of parent training and other behavioural interventions in the treatment of children and adolescents with attention deficit hyperactivity disorder

    Journal of Child Psychology and Psychiatry and Allied Disciplines, Vol. 59, Núm. 9, pp. 932-947

2017

  1. Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV, 2-Year, Open-Label Study in Europe

    CNS Drugs, Vol. 31, Núm. 7, pp. 625-638

  2. Systematic review of quality of life and functional outcomes in randomized placebo-controlled studies of medications for attention-deficit/hyperactivity disorder

    European Child and Adolescent Psychiatry, Vol. 26, Núm. 11, pp. 1283-1307

2014

  1. Post hoc analyses of the impact of previous medication on the efficacy of lisdexamfetamine dimesylate in the treatment of attention-deficit/ hyperactivity disorder in a randomized, Controlled trial

    Neuropsychiatric Disease and Treatment, Vol. 10, pp. 2039-2047

2013

  1. A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents

    CNS Drugs, Vol. 27, Núm. 9, pp. 743-751

  2. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder

    European Neuropsychopharmacology, Vol. 23, Núm. 10, pp. 1208-1218

  3. Health-related quality of life and functional outcomes from a randomized, controlled study of lisdexamfetamine dimesylate in children and adolescents with attention deficit hyperactivity disorder

    CNS Drugs, Vol. 27, Núm. 10, pp. 829-840

2004

  1. A prospective, multicenter, open-label assessment of atomoxetine in non-North American children and adolescents with ADHD

    European Child and Adolescent Psychiatry, Vol. 13, Núm. 4, pp. 249-257